Evotec and Novo Nordisk’s joint translational drug discovery initiative, LAB eN², has announced the selection of its first three research projects and an expansion to include five more leading academic institutions. LAB eN², launched in September 2023, aims to bridge
Evotec SE has announced the sale of its chemical API-focused CDMO facility, Evotec DS GmbH, located in Halle/Westphalia, Germany, to private equity firm Monacum Partners. The divestment is part of Evotec’s “Priority Reset” initiative, launched in April 2024, designed to
Evotec SE announced the expansion of its strategic partnership with Bristol Myers Squibb to further develop a molecular glue-based pipeline. Evotec has received a $50 million payment from Bristol Myers Squibb, with additional programme-based milestone payments contributing to the overall
Evotec has announced a strategic partnership with Novo Nordisk to advance the development of stem cell-based therapies. The collaboration focuses on creating next-generation off-the-shelf cell therapy products for clinical use, with the potential for commercialisation in the future. The agreement
Evotec SE has announced a new collaboration with X-Chem to advance early-stage drug discovery. The partnership will utilise X-Chem’s DNA-encoded library (DEL) technology to streamline the process of identifying potential drug candidates. X-Chem provides access to its DEL technology through
Evotec SE has announced the appointment of Dr. Christian Wojczewski as the company’s new Chief Executive Officer (CEO), effective from July 1, 2024. This follows the retirement of Dr. Mario Polywka, who has served as Interim CEO since January 3, 2024.
